| Date | Title | Description |
| 28.01.2026 | Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss | Dresden, Germany, and Lexington, MA, January 28, 2026 – Seamless Therapeutics announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company (“Lilly”) to develop and com... |
| 08.01.2026 | SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease | BARCELONA, January 8, 2026 – SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the Part B dose-... |
| 06.01.2026 | SpliceBio Appoints Don Munoz as Chief Financial Officer | BARCELONA, January 06, 2026 – SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced the appointment of Don Munoz as Chief Financial Officer.... |
| 01.07.2025 | UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss Rincell-1 addresses a multi $Bn global market opportunity whe... | Sheffield, UK, July 1 2025 – Rinri Therapeutics, a world leading company focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, is pleased to announce the approval of its Clinical Trial Application (CTA) f... |
| 11.06.2025 | SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines | BARCELONA, SPAIN, 11 June 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing co-led... |
| 03.04.2025 | Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline | South San Francisco, CA, April 3, 2025 – Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion o... |
| 21.03.2025 | SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease | BARCELONA, SPAIN, 13 March 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that it has dosed the first patient in the Phase 1/2... |
| 17.03.2025 | EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition | Mont-Saint-Guibert, Belgium (March 17, 2025) – EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be... |
| 01.03.2025 | Switch: Precision siRNA knockdown | San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue |
| 08.01.2025 | EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma | Mont-Saint-Guibert, Belgium (January 8, 2025) – EsoBiotec SA, a biotechnology company empowering cells in vivo to fight cancer, in collaboration with Pregene Biopharma, today announced the first patient has been dosed in an investigator-in... |
| 28.12.2024 | SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease | BARCELONA, SPAIN, 12 December 2024 – SpliceBio, a genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that the U.S. Food & Drug Administration (FDA) has cleared i... |
| 06.12.2024 | Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society | San Francisco, CA, December 6, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for epilepsy and other disorders of the nervous system, today announced positive clinical data from t... |
| 08.11.2024 | ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines | ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of delivering targeted genetic nanomedicines, today announces a collaboration with Eli Lilly and Company (“Lilly”). |
| 01.11.2024 | Editor’s pick: Switch Therapeutics | Each year, Nature Biotechnology highlights companies that have received sizeable early-stage
funding in the previous year. Switch Therapeutics is rethinking cell-type specificity, building
precision RNAi therapeutics for the brain. By Iris ... |
| 01.11.2024 | ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer | ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as Chief Executive Officer of ViaNautis. He will succeed Co-Founder a... |
| 15.04.2024 | Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases | CAMBRIDGE, Mass., April 15, 2024 — Walden Biosciences, Inc. (Walden), a private, venture-backed clinical development stage company focused on disease-modifying, transformative therapies for the treatment of kidney diseases, today announced ... |
| 08.02.2024 | Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders | San Francisco, CA, February 8, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of a ... |
| 13.11.2023 | ViaNautis is developing a nanovesicle platform designed to deliver genetic therapeutic payloads to the specific site of action with unparalleled precision. | Cambridge UK, 13 November 2023 – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, is excited to announce the successful completion of its Series A funding round, rais... |
| 26.10.2023 | Neurona's groundbreaking work is making waves in the media! Discover how stem cell-derived GABAergic neurons are transforming the lives of epilepsy patients by clicking the link below: | https://www.nbcnews.com/now/video/doctors-test-experimental-treatment-to-combat-seizures-in-epilepsy-patients-193764421687 |
| 17.10.2023 | SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease | BARCELONA, 17 October, 2023 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the signing of an exclusive collaboration and licensing agreement with... |
| 21.06.2023 | SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program | - |
| 15.06.2023 | Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases | - |
| 18.05.2023 | Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting | - |
| 16.03.2023 | ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19 | - |
| 16.03.2023 | Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology | - |
| 14.11.2022 | Code Biotherapeutics Names Alex S. Tracy, PhD, as Chief Technical Officer | Greater Philadelphia, Pa., November 14, 2022 – Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering the targeted delivery of precision genetic medicines, today announces the appointment of Alex Tracy, PhD, as Chief Tech... |
| 11.10.2022 | Walden Biosciences Appoints Peter Guest Linde, M.D. as Chief Medical Officer | CAMBRIDGE, Mass., Oct. 11, 2022 – Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that the Company has appointed Peter Guest Linde, ... |
| 28.09.2022 | Code Biotherapeutics Names David Anderson, PhD, as Chief Scientific Officer | Greater Philadelphia, Pa., September 28, 2022 — Code Biotherapeutics, Inc., (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announces the appointment of David Anderson, PhD, as Chief Sc... |
| 29.06.2022 | Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy | June 29, 2022 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the first patient dosed in a Phase 1/2 clinical trial of its l... |
| 07.06.2022 | Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases | Greater Philadelphia, Pa., June 7, 2022 — Code Biotherapeutics, Inc., (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized and oversubscribed Series A financing of $75 ... |
| 01.03.2022 | AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio | AbbVie, 01 March 2022: AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio. This acquisition gives AbbVie access to Syndesi’s portfolio o... |
| 16.02.2022 | SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline | SpliceBio, 16 February 2022: SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The financing was co-... |
| 15.12.2021 | EsoBiotec | 15 December 2021: EsoBiotec is a biotechnology company developing an in vivo engineering platform to produce cancer fighting cells inside the patient’s body. |
| 29.10.2021 | Walden: targeting podocytes as linchpin for kidney function | Walden, 29 October 2021: targeting podocytes as linchpin for kidney function. |
| 21.10.2021 | Syndesi Therapeutics announces commencement of dosing in clinical trial of SDI-118 in elderly subjects with cognitive impairment | Syndesi, 21 October 2021: Syndesi Therapeutics announces commencement of dosing in clinical trial of SDI-118 in elderly subjects with cognitive impairment. |
| 01.09.2021 | ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 | Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XV... |
| 18.08.2021 | ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody | Belgium, 18 August 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its ll... |
| 22.04.2021 | ExeVir’s CRO hunt for Phase II/III COVID-19 subQ antibody trial to start midyear, also USD 50– 100m Series B raise | 13 Jul 2021. ExeVir Bio will open its doors to CRO pitches mid-year for a Phase II/III trial investigating its
subcutaneously administered neutralizing antibody XVR011 in outpatient COVID-19 patients, CEO
Torsten Mummenbrauer said. Decision... |
| 19.04.2021 | Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy | 18 Jun 2021. Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders |
| 16.03.2021 | StrideBio Announces Closing of $81.5M Series B Financing | Research Triangle Park, N.C., Mar. 16, 2021 – StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised ... |
| 16.03.2021 | ExeVir Announces Close of US$50 million / EUR42 million Series A Financing | Belgium, March 16th, 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50... |
| 18.02.2021 | UCB Ventures and AXA Venture Partners: seeking innovation in digital health | 18 Feb 2021. In this interview, UCB Ventures Partner, Delphine Hajaji, connects with François Robinet, Founding and Managing Partner at AXA Venture Partners, to tell us more about why both organizations decided to collaborate. In particular... |
| 27.01.2021 | Syndesi Therapeutics announces positive results from two additional Phase I studies of its novel SV2A modulator SDI-118, providing strong support for the initiation of further clinical trials in cogni... | 27 January 2021. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, announces results from two Phase I studies of its l... |
| 14.12.2020 | Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNATargeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases | 14 Dec 2020. Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, today announced a $100 million Series B financ... |
| 06.10.2020 | Walden seeking to develop breakthrough medicines to reverse kidney disease progression. | 06 Oct 2020. Walden Biosciences, Inc. (Walden), a biotechnology company focused on transforming the treatment of kidney disease, today announced its launch with a $51 million Series A financing led by ARCH Venture Partners and UCB Ventures.... |
| 28.07.2020 | ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19 | 28 Jul 2020. ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family... |
| 19.12.2019 | Syndesi Therapeutics announces the expansion of its management team with the appointment of Torsten Madsen, MD, PhD as Chief Medical Officer. | 19 Dec 2019. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced Torsten Madsen MD, PhD has joined its m... |
| 10.12.2019 | Locana Expands Leadership Team with Appointment of former Casebia CEO as Chief Executive Officer | 10 Dec 2019. Locana, Inc., a leading RNA-targeting gene therapy company, today announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding the experienced leadership team and as part of a planned ... |
| 14.11.2019 | Sarepta and StrideBio Announce Multi-target Collaboration to Advance Novel Gene Therapies | 14 Nov 2019. Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a colla... |
| 04.09.2019 | Locana appoints Kathie Bishop, Ph.D., as Chief Scientific Officer | 04 Sep 2019. Locana, a leading RNA-targeting gene therapy company, today announced the appointment of Kathie M. Bishop, Ph.D. as chief scientific officer. Dr. Bishop is a neuroscientist and drug development leader with 20 years of pharmaceu... |
| 31.07.2019 | Ally secured seed finance from ARCH Venture Partners, Alta Partners and UCB Ventures to advance its novel gene therapy platform. | 31 July 2019. Ally secured seed finance from ARCH Venture Partners, Alta Partners and UCB Ventures to advance its novel gene therapy platform. |
| 28.03.2019 | StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases | 28 March 2019. Multi-target deal will utilize StrideBio's platform to identify unique AAV capsids for delivery of gene therapies targeting neurological diseases, including Friedreich's Ataxia. |
| 20.03.2019 | Syndesi Therapeutics awarded non-dilutive funding of up to €3.2M for development of its lead program, SDI-118, aimed at treating cognitive impairment | 20 March 2019. Developing novel SV2A modulators for cognitive impairment, today announced it has been granted up to EUR 3.2 M in non-dilutive funding from the Walloon Region. |
| 06.03.2019 | UCB Ventures Appoints Alicia Irurzun-Lafitte as Partner | 06 March 2019. UCB Ventures, the corporate venture arm of UCB Pharma, today announced that Alicia Irurzun-Lafitte will join UCB Ventures as Partner in Boston. Alicia brings 10 years of deal making experience, spanning business development t... |
| 19.02.2019 | CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement | 19 February 2019. CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene thera... |
| 03.01.2019 | StrideBio Appoints Sapan Shah, Ph.D. as Chief Executive Officer | 03 January 2019. StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the com... |
| 22.06.2018 | Read the interview with Erica Whittaker in BioCentury | 22 June 2018. Description: UCB Ventures' recent investment in Durham, N.C.-based gene therapy play StrideBio Inc. marks the next phase in how the strategic investor plans to deploy its €150 million ($174 million) fund. |
| 13.06.2018 | UCB Ventures makes its first direct investment | 13 June 2018. UCB Ventures announces its first direct investment in the oversubscribed $15.7 million Series A Financing Round for StrideBio, Inc., … |
| 01.02.2018 | UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics to develop novel therapeutics for cognitive disorders | 01 February 2018. We have recently announced the creation of Syndesi Therapeutic to further develop the research … |
| - | Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies | 22 May 2019. Locana, Inc., a leading RNA-targeting gene therapy company, announced today the close of a $55 million Series A financing led by ARCH Venture Partners with participation from Temasek and Lightstone Ventures, all existing invest... |
| - | Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator in development for treatment of cognitive impairment | 08 May 2019. Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced that its lead molecule, SDI-118, has entered into Phas... |
| - | Rinri Therapeutics secures £1.4 million seed funding to advance its novel regenerative cell therapy to treat sensorineural hearing loss | 20 May 2019. Rinri Therapeutics, a biotechnology company developing a novel cell- based therapy to restore hearing, announced today that it successfully secured £1.4 million in seed funding. The financing, which was co-led by Boehringer Ing... |
